A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer

Breast Neoplasms Clinical Trial

— D-Beyond  

Official title:

A Pre‐Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01864798
• Other study ID #: IJB-BCTL- 20119167
• Secondary ID: 2011-006224-21
• Status: Terminated
• Phase: Phase 2
• Start date: July 2013
• Est. completion date: January 2017

Study information

• Verified date: November 2018
• Source: Jules Bordet Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, single arm phase IIa trial in which patients with early breast cancer will receive pre-operatively two doses of denosumab 120mg subcutaneously one week apart (maximum 12 days) followed by surgery. Tumor, normal breast tissue and blood samples will be collected at baseline and at surgery. Post-operative treatment will be at the discretion of the investigator.

Primary objective: to determine if a short course of RANKL inhibition with denosumab can induce a decrease in tumor proliferation rates as determined by Ki67 immunohistochemistry (IHC) in newly diagnosed, early stage breast cancer in pre-menopausal women.

Secondary objectives:

• To determine the number of absolute Ki67 responders after a short course of denosumab (defined as <2.7% IHC staining in the post treatment tumor biopsy).

• To determine the effects of a short course of denosumab on serum C-terminal telopeptide levels (CTX).

• To determine the effects of a short course of denosumab on RANK/RANKL gene expression and signaling as assessed by immunohistochemistry (IHC) and RNA sequencing in the tumor.

• To determine the effect of a short course of denosumab on tumor apoptosis rates using IHC

• To determine the effect of a short course of denosumab on modulating the immature mammary epithelial cell populations in the tumor.

• To determine the effect of a short course of denosumab on estrogen signaling pathways in the tumor.

• To determine the effect of a short course of denosumab on various immune

• To determine effect of safety profile of denosumab

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 27
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female gender

2. Age = 18 years

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

4. Premenopausal status defined as the presence of active menstrual cycle or normal menses during the 6 weeks preceding the start of study treatment. Biochemical evidence of phase of menstrual cycle is required (estradiol, FSH and LH). In women previously exposed to hysterectomy,or were using hormonal intrauterine device at the time of enrolment, premenopausal levels of estradiol, FSH and LH are required to be eligible

5. Non-metastatic operable newly diagnosed primary invasive carcinoma of the breast that is:

1. Histologically confirmed

2. Primary tumor size greater than 1.5 cm, measured by any of clinical examination, mammography, ultrasound or magnetic resonance imaging

3. Any clinical nodal status

4. Fully operable and not fixed to chest wall.

6. Known HER2 status

7. Known estrogen receptor (ER) status and progesterone receptor status (PgR)

8. Patient has adequate bone marrow and organ function as shown by:

• Absolute neutrophil count (ANC) = 1.5 x 109/L

• Platelets = 100 x 109/L

• Hemoglobin (Hgb) = 9.0 g/dL

• Serum creatinine = 1.5 x ULN

• Total serum bilirubin = 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin = 3.0 x ULN, with direct bilirubin = 1.5 x ULN)

• AST and ALT = 1.5 x ULN

• Random blood sugar (RBS) = 200 mg/dL or = 11.1 mmol/L

• Glycosylated hemoglobin (HbA1c) = 8 %

9. Albumin-adjusted serum calcium = 8.0 mg/dL (= 2.0 mmol/L)

10. Women of childbearing potential must agree to use an active local contraception method for the duration of the study and for at least 7 months after the last dose of study treatment

11. Patients must accept to take calcium and vitamin D supplementation until the completion of the study treatment

12. Signed informed consent form (ICF) for all study procedures according to local regulatory requirements prior to beginning of the study

13. Patients must accept to make available tumor and normal tissue samples for submission to central laboratory at the Jules Bordet Institute, Brussels, Belgium, to conduct translational studies as part of this protocol.

Exclusion Criteria:

1. History of any prior (ipsi and/or contralateral) breast cancer

2. Any "clinical" T4 tumor defined by TNM including inflammatory breast cancer

3. History of non-breast malignancies within the 5 years prior to study entry (except carcinoma in situ of the cervix, of the colon, melanoma in situ and basal cell and squamous cell carcinomas of the skin)

4. Prior or planned systemic anti-cancer therapy before definitive surgery

5. Unhealed or planned dental/oral surgery, current or previous osteonecrosis or osteomyelitis of the jaw

6. Pregnant or lactating women or women of childbearing potential without a negative serum or urinary pregnancy test within 7 days prior to starting study treatment; irrespective of the method of contraception used

7. Active Hepatitis-B virus (HBV), Hepatitis-C virus (HCV) or human immunodeficiency virus (HIV) infection

8. Known hypersensitivity to denosumab

9. Bilateral invasive tumors

Related Conditions & MeSH terms

• Breast Neoplasms

Intervention

Drug:
• Denosumab

Locations

Country	Name	City	State
Australia	Royal Melbourne Hospital	Victoria
Belgium	Hopital Erasme	Brussels
Belgium	Institute Jules Bordet	Brussels
Belgium	UZ Leuven	Leuven
Belgium	CHU Ambroise Paré	Mons
Belgium	CMSE	Namur

Sponsors (2)

Lead Sponsor	Collaborator
Jules Bordet Institute	Melbourne Health

Countries where clinical trial is conducted

Australia,  Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PgR status (positive vs. negative)		Baseline and surgery at Day 10
Other	RANKL status (IHC positive vs. negative) in normal breast tissue		Baseline and surgery at Day 10
Other	RANKL status (IHC positive vs. negative) in infiltrating cells or stroma		Baseline and surgery at Day 10
Other	RANKL status (IHC positive vs. negative) in tumor tissue		Baseline and surgery at Day 10
Other	RANK status (IHC positive vs. negative) in normal tissue		Baseline and surgery at Day 10
Other	RANK status (IHC positive vs. negative) in tumor tissue		Baseline and surgery at Day 10
Primary	Geometric mean change in tumor Ki67 expression	Assessed by immunohistochemistry (IHC) from	Baseline and surgery at Day 10
Secondary	Absolute Ki67 responders	KI 67 responders will be defined as below 2.7% Ki67 IHC staining in the post treatment tumor biopsy	Baseline and surgery at Day 10
Secondary	C-terminal telopeptide (CTX) serum levels		Baseline and surgery at Day 10
Secondary	RANK/RANKL gene expression and signalling	Assessed by immunohistochemistry (IHC) and RNA sequencing profile in the tumor	Baseline and surgery at Day 10
Secondary	gene expression (AURKA, Ki-67,GGI)	Change in tumor proliferation rates using gene expression (single genes and gene modules, i.e. AURKA, Ki-67) and proliferation-related gene modules, i.e. GGI) in the tumor from baseline to prior to surgery	Baseline and surgery at Day 10
Secondary	TUNEL and caspase-3 apoptosis markers	Change in tumor apoptosis rates as measured using TUNEL and caspase-3 IHC from baseline to prior to surgery	Baseline and surgery at Day 10
Secondary	expression of immature mammary epithelial cell population: MaSCs, luminal progenitors , ALDH1	Change in expression levels from genes corresponding to immature mammary epithelial cell populations (MaSCs and luminal progenitors developed by Lim et al; Nature 2009), and in IHC expression of ALDH1, a stem cell marker in the tumor	Baseline and surgery at Day 10
Secondary	gene expression of the estrogen pathways (i.e. ESR1, PgR, BCL2) and estrogen-related gene expression modules (i.e. ESR module)	Change in expression levels from single genes related to the estrogen pathways (i.e. ESR1, PgR, BCL2 using both gene expression and IHC) and estrogen-related gene expression modules (i.e. ESR module) in the tumor	Baseline and surgery at Day 10
Secondary	immune related genes	Change in expression levels from single genes related to immune pathways using both gene expression and IHC, and in immune-related gene expression modules, to explore the hypothesis that RANKL can modulate T regulatory cells in the tumor	Baseline and surgery at Day 10
Secondary	Quantity of tumor infiltrating lymphocytes	Change in the quantity of tumor infiltrating lymphocytes as measured by percentage infiltration of surrounding tumor stroma and intra-tumoral on the H&E slide pre and post treatment	Baseline and surgery at Day 10
Secondary	Safety and tolerability of a short course of denosumab		Day 1, day 8 and surgery Day 10